ASX Announcements


 
    Application for quotation of securities - NEU  
 
    2023 Results webinar  
 
    Neuren reports profit of $157 million for 2023  
 
    Appendix 4E and 2023 full year accounts  
 
    Neuren 2023 results investor webinar on 29 February 2024  
 
    DAYBUE net sales US$87.1 million in Q4 2023  
 
    Comment on research report  
 
    Pause in Trading  
 
    Notification regarding unquoted securities - NEU  
 
    Application for quotation of securities - NEU  
 
    Q4 2023 Appendix 4C Cash Flow Report  
 
    Q4 2023 quarterly activity report  
 
    Completion of enrolment in Neuren's Angelman P2 trial  
 
    Application for quotation of securities - NEU  
 
    Investor presentation, 18 December 2023  
 
    P2 trial shows significant improvements in Phelan-McDermid  
 
    Trading Halt  
 
    Neuren completes enrolment in Pitt Hopkins Phase 2 trial  
 
    Comment on media speculation  
 
    Neuren completes Phelan-McDermid syndrome Phase 2 trial  
 
    Investor presentation, 8 November 2023  
 
    DAYBUE net sales US$66.9 million in Q3 2023  
 
    Q3 2023 quarterly activity and cash flow report  
 
    Change of Director's Interest Notice - J Basile  
 
    S&P DJI Announces September 2023 Quarterly Rebalance  
 
    Investor presentation, 28 August 2023  
 
    Neuren reports 2023 half-year profit after tax of $48m  
 
    Half Yearly Report and Accounts  
 
    Notification of half-year results & investor web conference  
 
    Q2 2023 quarterly activity and cash flow report  
 
    Neuren receives US$100m for expanded DAYBUE agreement  
 
    Investor web conference presentation, 14 July 2023  
 
    Neuren and Acadia expand global partnership for trofinetide  
 
    Neuren completes enrolment in Phelan-McDermid Phase 2 trial  
 
    Neuren opens first site in US for Prader-Willi Phase 2 trial  
 
    Change of Director's Interest Notice  
 
    Neuren receives US$40m milestone payment  
 
    Neuren presenting at Jefferies Global Healthcare Conference  
 
    Results of Meeting  
 
    AGM Chair Address & CEO Presentation  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Virtual AGM online guide  
 
    Q1 2023 quarterly activity and cash flow report  
 
    Appendix 4G  
 
    2022 Annual Report to shareholders  
 
    DAYBUE (trofinetide) launched in US - Neuren earns US$40m  
 
    Application for quotation of securities - NEU  
 
    Investor Presentation, 14 March 2023  
 
    Notification of investor webinar  
 
    FDA approves Daybue - the first treatment for Rett syndrome  
 
    Initial Director's Interest Notice  
 
    Neuren appoints Joe Basile to board of directors  
 
    Investor presentation, 1 March 2023  
 
    Investor Presentation, 24 February 2023  
 
    Neuren reports 2022 full-year results  
 
    Appendix 4E and 2022 full year accounts  
 
    Application for quotation of securities - NEU  
 
    Q4 2022 quarterly activity and cash flow report  
 
    Prader-Willi syndrome IND for NNZ-2591 approved by FDA  
 
    Neuren submits IND & first patients complete Phase 2 trials  
 
    Becoming a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Change in substantial holding  
 
    Q3 2022 quarterly activity and cash flow report  
 
    Neuren receives US$10 million milestone payment  
 
    Investor presentation, 14 September 2022  
 
    Rett Syndrome NDA accepted for Priority Review by FDA  
 
    Half-year shareholder update  
 
    Half Yearly Report and Accounts  
 
    Investor presentation, 8 August 2022  
 
    Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Acadia submits Rett Syndrome New Drug Application to the FDA  
 
    Neuren commences Phase 2 trial of NNZ-2591 in Angelman  
 
    Notification regarding unquoted securities - NEU  
 
    Neuren appoints Chief Medical Officer in United States  
 
    Results of Meeting  
 
    AGM Chairman's Address & CEO Presentation  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Virtual AGM online guide  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change in substantial holding  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial  
 
    FDA approval for Phelan-McDermid IND and Phase 2 trial  
 
    Ethics approval for Angelman Phase 2 trial in Australia  
 
    Investor presentation 25 Feb 2022  
 
    FDA approval for Angelman IND and Phase 2 trial  
 
    2021 Results - a transformational year for Neuren  
 
    Preliminary Final Report and 2021 Full Year Accounts  
 
    Notification regarding unquoted securities - NEU  
 
    Neuren appoints Vice President, Corporate Development  
 
    Q4 2021 quarterly activity and cash flow report  
 
    Becoming a substantial holder  
 
    Positive topline results from Phase 3 trial in Rett syndrome  
 
    Neuren presenting at Bell Potter Healthcare Conference  
 
    Q3 2021 quarterly activity and cash flow report  
 
    Neuren receives feedback on IND for Phelan-McDermid syndrome  
 
    Change of Director's Interest Notice - D Angus  
 
    US patent to 2034 granted for Neuren's NNZ-2591 in autism  
 
    Change of Director's Interest Notice - J Harry  
 
    Change of Director's Interest Notice - J Pilcher  
 
    Change of Director's Interest Notice - P Davies  
 
    Application for quotation of securities - NEU  
 
    Update - Proposed issue of securities - NEU  
 
    $3.3 million raised from oversubscribed SPP  
 
    Feedback on Angelman IND and submission of Pitt Hopkins IND  
 
    IND application submitted for NNZ-2591 in Phelan-McDermid  
 
    Share Purchase Plan Offer Booklet  
 
    Section 708A Notice  
 
    New patent issued to 2032 for Neuren's trofinetide in Brazil  
 
    Application for quotation of securities - NEU  
 
    Investor Presentation, 13 September 2021  
 
    Proposed issue of securities - NEU  
 
    Placement to accelerate NNZ-2591 across 4 indications  
 
    Notification of investor presentation, 9.00 AEST 13 Sept 21  
 
    Trading Halt  
 
    FDA grants Orphan Drug designation for Prader-Willi syndrome  
 
    Angelman IND and Ethics applications submitted for NNZ-2591  
 
    Trofinetide Rett syndrome clinical trial in girls aged 2-5  
 
    R&D Tax Incentive Advance Overseas Finding Approval  
 
    Half-year shareholder update  
 
    Half Yearly Report and Accounts  
 
    Notification of investor webinar  
 
    Phase 3 enrolment successfully completed, results in Q4 2021  
 
    Q2 2021 quarterly activity and cash flow report  
 
    Change of Director's Interest Notice  
 
    Results of Meeting  
 
    AGM Chairman's Address and CEO Presentation  
 
    Change of Director's Interest Notice  
 
    Investor presentation, 15 June 2021  
 
    Initial Director's Interest Notice  
 
    Neuren CEO Jon Pilcher appointed to board of directors  
 
    Neuren to present at MST Access investor conference  
 
    Update - Annual General Meeting 2021  
 
    Positive FDA meetings enable INDs for three Phase 2 trials  
 
    Virtual AGM online guide  
 
    Notice of Annual General Meeting/Proxy Form  
 
    New patent issued to 2032 for Neuren's trofinetide in Canada  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Quarterly report and cash flow statement for Q1 2021  
 
    Investor presentation, 23 March 2021  
 
    Neuren successfully completes manufacturing for Phase 2  
 
    Neuren corporate presentation, 24 February 2021  
 
    Neuren approaching transforming milestones in 2021  
 
    Preliminary Final Report and 2020 full year accounts  
 
    Change of Director's Interest Notice  
 
    Notification of investor briefing webinar  
 
    Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline  
 
    Successful Phase 1 trial for Neuren's NNZ-2591  
 
    Quarterly report and cash flow statement for Q4 2020  
 
    European Commission grants 3 NNZ-2591 Orphan designations  
 
    Notification of investor briefing webinar  
 
    Positive opinion for all 3 Orphan applications in Europe  
 
    Approval received for final stage of NNZ-2591 clinical trial  
 
    Quarterly report and cash flow statement for Q3 2020  
 
    Neuren requests Orphan designations for NNZ-2591 in Europe  
 
    Neuren initiates manufacture of NNZ-2591 for Phase 2 trials  
 
    Half-year Shareholder Update  
 
    Half Yearly Report and Accounts  
 
    Corporate presentation, 18 August 2020  
 
    Change of Director's Interest Notice  
 
    Appendix 2A  
 
    Change of Director's Interest Notice  
 
    Completion of Share Purchase Plan  
 
    Appointment of CFO & Company Secretary  
 
    Q2 2020 Activity Report and Cash Flow Report  
 
    Final share buy-back notice - Appendix 3F  
 
    Announcement of buy-back - Appendix 3C  
 
    Publications and presentations for trofinetide and NNZ-2591  
 
    Appendix 3G  
 
    Share Purchase Plan Offer Booklet  
 
    Section 708A notice  
 
    Appendix 2A  
 
    Electing to receive SPP documents by e-mail  
 
    Results of Meeting  
 
    AGM Chairman's Address and CEO Presentation  
 
    Proposed issue of Securities - NEU  
 
    Neuren successfully completes $20m capital raising  
 
    Trading Halt  
 
    Temporary enrolment pause ended in Phase 3 trial in the US  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Virtual AGM online guide  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Neuren announces changes to leadership team  
 
    Neuren commences first clinical trial for NNZ-2591  
 
    Appendix 4G  
 
    Annual Report 2019  
 
    Appendix 4C - quarterly  
 
    Q1 2020 Activity Report  
 
    Corporate presentation, 6 April 2020  
 
    First patent in Israel granted for trofinetide  
 
    Change of Director's Interest Notice  
 
    International institution acquires 14% of Neuren  
 
    Change of Director's Interest Notice  
 
    Temporary pause in new enrolments for LAVENDER trial in US  
 
    Trading Halt  
 
    Neuren to capture substantially greater value after Phase 3  
 
    Additional information  
 
    Compelling results for 2591 dose ranging study in PMS model  
 
    Commentary on potential benefit to Neuren of RPD designation  
 
    Rare Pediatric Disease designation received from FDA  
 
    5 Orphan Drug programs and Rett in Phase 3 funded by partner  
 
    Appendix 4E and 2019 full year accounts  
 
    Update on trofinetide Phase 3 trial in Rett syndrome  
 
    Appendix 4C - quarterly  
 
    2019 year-end update and 2020 outlook  
 
    Patent to 2034 granted in Europe for Neuren's NNZ-2591  
 
    Phase 3 trial of trofinetide in Rett syndrome commences  
 
    Neuren Corporate Presentation, October 2019  
 
    Appendix 4C - quarterly  
 
    FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins  
 
    Pause in Trading  
 
    FDA grants Orphan Drug Designation for NNZ-2591 in Angelman  
 
    Neuren approaching key milestones in Q4 2019  
 
    Neuren advances pipeline for neurodevelopmental disorders  
 
    Half Yearly Report and Accounts  
 
    New patent granted for Neuren's NNZ-2591 in Japan  
 
    Appendix 4C - quarterly  
 
    Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA  
 
    Neuren receives final payment from Lanstead Capital  
 
    Results of Meeting  
 
    Chairman's Address at 2019 Annual Meeting of Shareholders  
 
    Validation for NNZ-2591 neurodevelopmental disorder pipeline  
 
    NNZ-2591 positive effects in Pitt Hopkins syndrome model  
 
    NNZ-2591 positive effects in Angelman syndrome model  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Update on development plan for NNZ-2591  
 
    Neuren's Rett syndrome Phase 2 trial published in Neurology  
 
    Fundamentals strong as Neuren advances neuroscience pipeline  
 
    Preliminary Final Report and statutory accounts  
 
    NNZ-2591 positive effects in Phelan-McDermid syndrome model  
 
    Plans for Phase 3 trial in Rett syndrome  
 
    Neuren retains ex-North America, appoints investment bank  
 
    Appendix 4C - quarterly  
 
    Final Director's Interest Notice  
 
    Ceasing to be a substantial holder  
 
    2018 Year-end Business Update  
 
    Larry Glass to retire as a director and continue as CSO  
 
    Presentation at AusBiotech Invest and Partnering 2018  
 
    Appendix 4C - quarterly  
 
    Trofinetide ex-North America exclusive negotiation period  
 
    Neuren and ACADIA hold Rett syndrome SAB meeting  
 
    Change of Director's Interest Notice  
 
    FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID  
 
    Investor presentation, 6 September 2018  
 
    Half Yearly Report and Accounts  
 
    Neuren and Lanstead agree to pause settlements for 120 days  
 
    Appointment of auditor  
 
    Neuren receives initial payment of US$10 million from ACADIA  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Investor update  
 
    Neuren and ACADIA announce agreement for North America  
 
    Appendix 4C - quarterly  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Neuren announces new appointments to the board of directors  
 
    Results of Meeting  
 
    Chairman's Address at 2018 Annual Shareholders' Meeting  
 
    Change of Director's Interest Notice  
 
    Final share buy-back notice - Appendix 3F  
 
    Announcement of buy-back - Appendix 3C  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Neuren announces investment and exclusive negotiation period  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Appendix 4C - quarterly  
 
    First patent in Japan granted for Neuren's trofinetide  
 
    Full Year Statutory Accounts  
 
    Disclosure under Listing Rule 4.3D  
 
    Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    Final Director's Interest Notice  
 
    Non-executive director retirement  
 
    Change in substantial holding  
 
    Neuren announces new US patent to be granted for NNZ-2591  
 
    Consolidation/Split - NEU  
 
    Notification under Listing Rule 7.20 of share reorganisation  
 
    Appendix 4C - quarterly  
 
    Neuren FDA meeting confirms Phase 3 plan for Rett syndrome  
 
    Investor presentation, 6 October 2017  
 
    Presentations and publication for Rett syndrome trials  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Neuren reports 2017 half-year results  
 
    Half Yearly Report and Accounts  
 
    Notice of special meeting of shareholders  
 
    Appendix 4C - quarterly  
 
    Becoming a substantial holder  
 
    Neuren granted Type B Meeting with FDA for Rett syndrome  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Meeting  
 
    2017 AGM Chairman's Address  
 
    Neuren secures funding for key activities for Rett syndrome  
 
    Response to ASX Price Query  
 
    Trading Halt  
 
    Investor presentation, 2 June 2017  
 
    Neuren announces grant of two new patents to 2032  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Response to Appendix 4C Query  
 
    Appendix 4C - quarterly  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Neuren receives $1 million R&D Tax Incentive  
 
    Investor presentation, 3 April 2017  
 
    Full Year Statutory Accounts  
 
    Trofinetide significant clinical benefit in Rett syndrome  
 
    Trading Halt  
 
    Preliminary Final Report  
 
    Investor presentation, 2 February 2017  
 
    Appendix 4C - quarterly  
 
    Neuren completes Phase 2 trial in pediatric Rett syndrome  
 
    Results of Meeting  
 
    Investor presentation, 25 November 2016  
 
    Notice of special meeting of shareholders  
 
    Neuren completes enrolment in Rett syndrome Phase 2 trial  
 
    Appendix 4C - quarterly  
 
    Neuren receives $0.9m from exercise of last expiring options  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Neuren expands Phase 2 Rett syndrome pediatric trial  
 
    Appendix 4C - quarterly  
 
    Neuren presents at Rettsyndrome.org 2016 Research Symposium  
 
    Grant of new patent for Autism Spectrum Disorders  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Change of Director's Interest Notice  
 
    Presentation at 6th Annual TBI Conference, Washington DC  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4C - quarterly  
 
    Neuren Shareholder Update  
 
    Results of Phase 2 trial in moderate to severe TBI  
 
    Trading Halt  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    First subject commences Neuren's Rett syndrome Phase 2 trial  
 
    Neuren reports 2015 full-year financial results  
 
    Appendix 4E and Financial Report 31 December 2015  
 
    Appendix 4C - quarterly  
 
    Neuren Investor Presentation, 11 January 2016  
 
    Neuren Shareholder Update, January 2016  
 
    Appendix 3B  
 
    Trofinetide successful in Phase 2 trial in Fragile X  
 
    Trading Halt  
 
    Grant of composition patent in Europe for Neuren's NNZ-2591  
 
    Corporations Act Notice  
 
    Appendix 3B  
 
    Shareholders provide further support for Rett syndrome  
 
    Neuren completes enrolment in INTREPID clinical trial  
 
    Appendix 4C - quarterly  
 
    IRSF confirms financial support for Neuren's clinical trials  
 
    New US patent covering use of trofinetide for Rett syndrome  
 
    Neuren provides update on Fragile X and INTREPID trials  
 
    Half Yearly Report and Accounts 30 June 2015  
 
    trofinetide confirmed as INN for Neuren's NNZ-2566  
 
    Neuren confirms orphan drug designations in Europe  
 
    Investor presentation, 31 July 2015  
 
    Appendix 4C - quarterly  
 
    Neuren reports progress in orphan drug programs  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Neuren receives response to request for Breakthrough Therapy  
 
    Neuren reports 2014 full-year financial results  
 
    Preliminary Final Report and 2014 full year accounts  
 
    FDA grants Neuren Orphan Drug designation for Rett syndrome  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Updated Share Trading Policy  
 
    Neuren announces trofinetide as proposed INN for NNZ-2566  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Investor Presentation, 8 January 2015  
 
    Response to ASX Price Query  
 
    Neuren submits Orphan Drug/Breakthrough Therapy applications  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Investor presentation, 27 November 2014  
 
    Appendix 3B  
 
    Neuren successful in Rett syndrome Phase 2 trial  
 
    Trading Halt  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Issue of long term incentives  
 
    Neuren to release Rett Syndrome trial results in November  
 
    Enrolment commences in Neuren's Concussion Phase 2 trial  
 
    Investor presentation, 4 September 2014  
 
    Appendix 3B  
 
    Neuren reports 2014 half-year financial results  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B  
 
    Neuren advances NNZ-2591 towards IND application  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    US$3m increase to US Army grant and INTREPID outlook update  
 
    Neuren receives ethics approval to start Concussion trial  
 
    Neuren completes enrolment in Phase 2 trial in Rett Syndrome  
 
    Appendix 3B  
 
    Neuren appoints CMC expert to leadership team  
 
    Neuren receives new US patent for NNZ-2591  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren presents at International Meeting for Autism Research  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    AGM Results of Meeting  
 
    Chairman's AGM Address to Shareholders  
 
    Presentation at Morgans Emerging Companies Conference  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Neuren reports financial results for 2013  
 
    Preliminary Final Report and audited Financial Statements  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Neuren reports progress in NNZ-2566 clinical trial programs  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Share Purchase Plan raises $2 million  
 
    Ceasing to be a substantial holder  
 
    Investor presentation, 19 November 2013  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Share Purchase Plan record date  
 
    SPP Certification  
 
    Appendix 3B  
 
    Becoming a substantial holder  
 
    Share Purchase Plan offer documents  
 
    Appendix 4C - quarterly  
 
    Orphan drug designation from FDA for NNZ-2566 in Fragile X  
 
    Section 708A(5)e Notice  
 
    Appendix 3B  
 
    Placement of $21.5m to accelerate execution of strategy  
 
    Neuren receives Fast Track designation for Fragile X  
 
    Trading Halt  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Investor presentation  
 
    Neuren data presented at Fragile X Foundation meeting  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Neuren opens new IND for NNZ-2566 in Fragile X Syndrome  
 
    Final Director's Interest Notice  
 
    Neuren announces changes to its leadership team  
 
    Half Yearly Report and Accounts  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Response to social media commentary re Rett trial  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Appendix 4C - quarterly  
 
    Investor presentation July 2013  
 
    Appendix 3B Option Exercise  
 
    Results in Fragile X Model with NNZ 2591  
 
    Response to ASX Price Query  
 
    Neuren receives two new patents  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise amended  
 
    Appendix 3B Option Exercise  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise  
 
    Response to ASX Price Query Letter  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise  
 
    FDA Fast Track granted for NNZ2566 Rett program  
 
    Change of Director's Interest Notice  
 
    Appendix 3B Equity Performance Rights  
 
    Appendix 3B Loan Funded Shares  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    CFO appointment  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Appendix 3B Exercise of Options  
 
    Lapse of Unlisted Options  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Investor Presentation May 2013  
 
    Results of Meeting  
 
    CEO Presentation to AGM  
 
    Chairman's Address to AGM  
 
    Response to ASX Price Query Letter  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Shareholder Update  
 
    Ceasing to be a substantial holder  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Initial Director's Interest Notice  
 
    Dr Richard Treagus joins Neuren Board  
 
    Appendix 4C - quarterly  
 
    Neuren appoints Nancy Jones SD Clinical & Medical Affairs  
 
    Neuren IND open for Rett Phase II trial  
 
    Appendix 3B  
 
    Neuren TAP Conference presentation and Fragile X results  
 
    Neuren completes Phase I NNZ2566 study/files Phase II IND  
 
    Amended 2 - Change in substantial holding  
 
    Amended Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 4C - quarterly  
 
    Response to ASX Price Query  
 
    NNZ2566 selected as Windhover Top 10 Neuroscience Project  
 
    Half Yearly Report and Accounts  
 
    Neuren appoints Joe Horrigan VP Clinical and Medical Affairs  
 
    NNZ2566 Rationale in ASDs  
 
    Appendix 4C - quarterly  
 
    Neuren awarded Rett Syndrome trial grant  
 
    Final Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Results of Meeting  
 
    CEO's address to AGM  
 
    Neuren announces cancer xenograft testing results  
 
    Change in substantial holding  
 
    Rett Syndrome pre-IND meeting held with FDA  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 4C - quarterly  
 
    Appendix 3B (exercise of options)  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Response to ASX Price Query  
 
    Neuren 2011 Annual Report  
 
    Initial Director's Interest Notice  
 
    Neuren appoints Bruce Hancox to board of directors  
 
    Neuren presentation to Arrowhead TBI Conference  
 
    Neuren 2011 Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    Neuren to proceed with oral NNZ2566 trial  
 
    Change in substantial holding  
 
    Response to ASX Price Query  
 
    Neuren Completes Phase II trial Cohort 2  
 
    Appendix 3B (exercise of options)  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 4C - quarterly  
 
    Appendix 3B (amendment)  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Half Yearly Report and Accounts  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Neuren places $3m of rights issue shortfall  
 
    Appendix 4C - quarterly  
 
    NEU Broker Presentation July 2011  
 
    Neuren CEO presentation to Bioshares Biotech Summit  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Results of Neuren Rights Issue  
 
    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
    Appendix 3B  
 
    CEO presentation to AusBiotech New York  
 
    Rights Issue Eligible Shareholder Notice  
 
    Change in substantial holding  
 
    Rights Issue Notice to Foreign Shareholders  
 
    Rights Issue Notice to Optionholders  
 
    Rights Issue Notice under Section 708AA  
 
    Appendix 3B (renounceable rights issue)  
 
    Neuren Rights Issue Letter of Offer (Australian residents)  
 
    Neuren Rights Issue Offer Document (NZ residents)  
 
    Neuren announces Renounceable Rights Issue  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Neuren completes placement and converts remaining note  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Annual Meeting  
 
    Results of Special Meeting  
 
    Neuren CEO Presentation to AGM  
 
    Neuren reduces outstanding convertible note principal  
 
    Neuren's Perseis selects lead antibodies  
 
    Notice of Special Shareholders Meeting/Proxy Form  
 
    Neuren Completes Phase II trial Cohort 1  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Becoming a substantial holder  
 
    Neuren Announces Private Placement and Rights Issue  
 
    Trading Halt  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Annual Report to shareholders  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Response to ASX Price Query  
 
    Notice of Special Shareholders Meeting  
 
    Preliminary Final Report  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Lapse of unquoted options  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Appendix 3B (amended)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Securities Trading Policy  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Initiates NNZ2566 Oral Formulation Development  
 
    Neuren Completes Additional Phase I Study for TBI  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Lapse of unquoted options  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    SpringTree becomes a substantial shareholder  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Appendix 3B  
 
    Results of Meeting  
 
    CEO Presentation to AGM  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Starts Phase II Trial of NNZ2566  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Lapse of unquoted options  
 
    Annual Report to shareholders  
 
    Appendix 3B - ESOP  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Grant funding for TFF oncology program  
 
    Trial of Second Neuren Drug Motiva to be Initiated  
 
    Preliminary Final Report  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (shares)  
 
    Appendix 3B (options)  
 
    Ceasing to be a substantial holder  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cato strategic partnership and appoints US CMO  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Neuren Completes Shareholder Approved Funding  
 
    Results of Special Shareholders Meeting  
 
    Initial Director's Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice of Special Shareholders Meeting  
 
    Dr John Holaday joins Neuren Board  
 
    Appendix 3B (notes)  
 
    Appendix 3B (options)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Neuren Arranges up to AU$7.8m in New Funding  
 
    Appendix 3B (shares)  
 
    Reinstatement to Official Quotation  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Appendix 4C - quarterly  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Reponse to Price Query  
 
    Half Year Report and Accounts  
 
    Appendix 3B  
 
    Neuren raises NZ$1 million through SPP  
 
    Appendix 4C - quarterly  
 
    Neuren SPP section 708A notice  
 
    SPP NZ Certification  
 
    Neuren NNZ-2566 Development Overview  
 
    Neuren Share Purchase Plan  
 
    Neuren Chairmans SPP Letter  
 
    SPP terms update  
 
    Neuren Share Purchase Plan  
 
    Ceasing to be a substantial holder  
 
    Neuren obtains further US$14m US Army funding  
 
    Results of Meeting  
 
    Presentation to AGM  
 
    Chairman's Address to Shareholders  
 
    Response to ASX Query - Appendix 4C  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Neuren Progresses Cancer Program  
 
    Trading Halt  
 
    Response to ASX Price Query  
 
    Trading Halt  
 
    Lapse of unquoted options  
 
    Annual Report to shareholders  
 
    Final Director's Interest Notice  
 
    Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    Neuren Strategy Update  
 
    Respone to ASX price query  
 
    Trading Halt  
 
    Change of Director's Interest Notice  
 
    Neuren Announces Glypromate Trial Preliminary Results  
 
    Phase 3 trial data collection completed  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Neuren raises $2m through underwritten SPP  
 
    Appendix 3B  
 
    US Army to provide additional NNZ2566 trial funding  
 
    Half Yearly Report and Accounts  
 
    Results of Special Shareholders' Meeting  
 
    Neuren extends SPP closing date  
 
    Neuren signs cancer license and collaboration agreement  
 
    NZ Securities Act certification for SPP  
 
    Share Purchase Plan letter to eligible shareholders  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Change in substantial holding  
 
    Notice of Special Meeting  
 
    Neuren Share Purchase Plan  
 
    Appendix 3B  
 
    Neuren raises a minimum of $3 million  
 
    Reinstatement to Official Quotation  
 
    Voluntary Suspension extended  
 
    Appendix 4C - quarterly  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Glypromate and NNZ 2566 in Top 10 Neuroscience Projects  
 
    NEU Completes Glypromate Phase 3 Recruitment  
 
    Neuren to get early results from Glypromate trial  
 
    Results of Meeting  
 
    CEO presentation to AGM  
 
    Response to ASX Query re: Appendix 4C  
 
    Positive interim safety analysis for Glypromate  
 
    Appendix 4C - quarterly  
 
    Quarterly Update to Shareholders April 2008  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Co-CEOs remuneration packages  
 
    Appendix 4E Preliminary Final Report  
 
    Appendix 3B  
 
    Form 604  
 
    Becoming a substantial holder  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Rights issue raises $7.1m and notes convert  
 
    Substantial shareholder notice  
 
    Change in substantial holding  
 
    Appendix 3B - shares issued on conversion of notes  
 
    Appendix 3B - allotment of rights issue underwriter shares  
 
    Notice under section 708A(5)(e)  
 
    Appendix 3B - allotment of rights issue shares  
 
    Neuren Appendix 4C December 2007  
 
    Results of Rights Issue  
 
    US Department of Defense Approves NNZ2566 Funding  
 
    Glypromate trial recruits 100th patient  
 
    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
    Section 708AA Notice  
 
    Foreign Shareholder Notice re Rights Issue  
 
    Shareholder Notice re Rights Issue  
 
    Optionholder Notice re Rights Issue  
 
    Section 708AA Notice  
 
    Appendix 3B - Non-renounceable Rights Issue  
 
    Rights Issue NZ Investment Statement and Prospectus  
 
    Rights Issue Letter of Offer  
 
    D Clarke Appendix 3Z  
 
    Neuren announces non-renounceable rights issue  
 
    Trading Halt  
 
    Neuren Clinical Development Update  
 
    Neuren Corporate Update December 2007  
 
    Neuren announces reorganisation  
 
    NNZ-2566 successful Phase 1b trial results  
 
    Appendix 4C - quarterly  
 
    Neuren completes acquisition of Hamilton Pharmaceuticals  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B - issue of convertible notes  
 
    Appendix 3B - issue of shares  
 
    Results of Meeting  
 
    Notice of Special Meeting of Shareholders  
 
    Neuren launches Australian Phase 3 Trial Sites  
 
    Neuren completes moderate TBI safety trial  
 
    Change in substantial holding  
 
    NZ arm of Phase 3 trial commences  
 
    Half Yearly Report and Accounts  
 
    Corporate Update Presentation  
 
    Commitments test entity - second quarter  
 
    Acquisition of Motiva through Hamilton Pharmaceuticals  
 
    Lapse of Unquoted Options  
 
    Cambridge University Alliance  
 
    First patient enters Glypromate Phase 3 trial  
 
    Revised Constitution  
 
    2007 AGM Results  
 
    CEO Presentation AGM  
 
    Bachem Glypromate Collaboration  
 
    Clinical Trials Update May 2007  
 
    Commitments Test Entity - First Quarter Report  
 
    Notice of Annual General Meeting  
 
    Annual Report  
 
    Change of Director's Interest Notice  
 
    Substantial Security Holder Notice  
 
    Preliminary Final Report  
 
    Neuren scientist receives Laureate award  
 
    Appendix 3B - ESOP options exercised  
 
    Further Validation of NNZ-2566 as TBI Treatment  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    US FDA approves Phase 3 IND for Glypromate Trial  
 
    Appendix 3B - escrow period ending 3 February 2007  
 
    Appendix 3B  
 
    Successful NNZ-2566 safety trial results  
 
    CEO Presentation to Investors and Partners Jan 2007  
 
    Engages Burrill to progress out-licensing  
 
    Partnering Update Presentation  
 
    Appendix 3B  
 
    Raises $1.6million  
 
    Commitments Test Entity - Third Quarter Report  
 
    Letter to shareholders re SPP extension  
 
    Preclinical results show cancer regression  
 
    Extends SPP  
 
    NNZ 2591 positive memory loss reversal results  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Positive Preclinical Results for NNZ-3006  
 
    Neuren Share Purchase Plan Disclosures  
 
    Update for Shareholders Sept 2006  
 
    Appendix 3B - Placement shares  
 
    A$6.0 million Share placement & Share Purchase Plan  
 
    Half Yearly Report  
 
    Glypromate Phase 2 Trial with US Army  
 
    Glypromate Phase 2 trial final results  
 
    ASX Waiver for reporting results of IFRS transition periods  
 
    Neuren to present NNZ2566 Phase 2 Strategy  
 
    Neuren presentation to US Army conference  
 
    Selects candidate for oral treatment of Parkinsons  
 
    Commitments Test Entity - Second Quarter Report  
 
    Appendix 3B  
 
    Appoints Chief Operating Officer  
 
    Nerve Protection Compounds Research Published  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Further US Army results presented on NNZ-2566  
 
    Granted US patent for NNZ-2566  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Results of AGM  
 
    Neuren AGM CEO Presentation  
 
    Commitments Test Entity - First Quarter Report  
 
    Neuren & US Army NNZ 2566 brain seizure results  
 
    CEO Pipeline & Strategy Update  
 
    Becoming a substantial holder  
 
    Reports successful Phase 2 results  
 
    Presentation to US Conferences  
 
    Notice of Annual General Meeting  
 
    Annual Report  
 
    Preclinical results for oral administration of NNZ-2566  
 
    NNZ-2566 Phase 1 trial to commence  
 
    Preliminary Final Report  
 
    Investor Update February 2006  
 
    FDA pre-clinical requirements to Phase 3 completed  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    Appendix 3B End of Restriction Period  
 
    Letter to Shareholders re Share Placement  
 
    Short Form Prospectus  
 
    Capital Raising Presentation November 2005  
 
    Appendix 3B  
 
    Neuren raises $6.4 million in share placement  
 
    Reinstatement to Official Quotation  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Neuren Agreement with Jackson Foundation for Phase 3  
 
    Neuren Senior Scientist inducted to US Institute of Medicine  
 
    Commitments Test Entity - Third Quarter Report  
 
    Presentation Market Update - Oct 2005  
 
    Neuren Wins NZ Biotechnology Co of the Year Award  
 
    Response to ASX Share Price Query  
 
    Parkinsons & Hypertension patents issued  
 
    Half Yearly Report & Half Year Accounts  
 
    Neuren initiates Phase 2 trial  
 
    US Army Presents Neuren Research Results  
 
    Appendix 3B  
 
    Commitments Test Entity - Second Quarter Report  
 
    Walter Reed NNZ-2566 Contract Expanded  
 
    FDA advances Neuren to Phase  
 
    Results of Annual General Meeting  
 
    AGM - CEO Presentation  
 
    Appendix 3B  
 
    Commitments Test Entity - First Quarter Report  
 
    Annual Report 2004 & Notice of AGM  
 
    Annual Report 2004  
 
    Neuren CEO Update March 2005  
 
    Walter Reed Collaboration  
 
    Change of Director's Interest Notice (NZ Disclosure) x2  
 
    Change of Director's Interest Notice x2  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Neuren & Metabolic NRP Collaboration  
 
    Preliminary Final Report  
 
    Initial Director's Interest Notice x17 (NZ Disclosures)  
 
    Initial Director's Interest Notice x 5  
 
    Former Pfizer Executive to join board  
 
    Neuren lists on ASX  
 
    Annual Report & Financial Statements - y/e 31/12/01  
 
    Annual Report & Financial Statements - y/e 31/12/02  
 
    Annual Report & Financial Statements - y/e 31/12/03  
 
    Annual Report & Financial Statements - y/e 31/12/03  
 
    Annual Report & Financial Statements - p/e 31/12/02  
 
    Half Year Directors' Report & Interim Financial Statements  
 
    Distribution Schedule  
 
    Share Option Plan  
 
    Constitution  
 
    Top 20 shareholders  
 
    Conditions for admission to official list  
 
    Appendix 1A - Application for admission to official list  
 
    Circualar re: Commencement of Official Quotation  
 
    Admission to Official List  
 
    Supplementary Disclosure Document  
 
    Disclosure Document